Tsveta Milanova Sells 2,804 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 2,804 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Agios Pharmaceuticals Stock Up 2.2 %

AGIO stock opened at $35.90 on Friday. The business’s 50-day moving average price is $46.77 and its 200-day moving average price is $45.50. The stock has a market cap of $2.05 billion, a P/E ratio of 3.16 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a twelve month low of $20.96 and a twelve month high of $62.58.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC raised its position in shares of Agios Pharmaceuticals by 1.1% during the 2nd quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock valued at $243,822,000 after purchasing an additional 63,900 shares during the period. State Street Corp increased its stake in Agios Pharmaceuticals by 10.2% in the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after buying an additional 216,484 shares in the last quarter. Erste Asset Management GmbH bought a new stake in Agios Pharmaceuticals during the third quarter valued at about $97,199,000. Geode Capital Management LLC lifted its position in shares of Agios Pharmaceuticals by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after acquiring an additional 6,101 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in shares of Agios Pharmaceuticals by 307.8% in the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after acquiring an additional 855,739 shares during the period.

Wall Street Analysts Forecast Growth

AGIO has been the topic of several research analyst reports. Raymond James reissued an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.